Aethlon Medical
Market Cap
US$28.1m
Last Updated
2021/02/26 00:01 UTC
Data Sources
Company Financials +
Executive Summary
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. More Details
Risk Analysis
Earnings are forecast to decline by an average of 47.6% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 3 more risks
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has Aethlon Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AEMD is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: AEMD's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
-11.1%
AEMD
-2.7%
US Medical Equipment
-3.2%
US Market
1 Year Return
-22.7%
AEMD
31.8%
US Medical Equipment
38.9%
US Market
Return vs Industry: AEMD underperformed the US Medical Equipment industry which returned 29.5% over the past year.
Return vs Market: AEMD underperformed the US Market which returned 37.1% over the past year.
Shareholder returns
| AEMD | Industry | Market | |
|---|---|---|---|
| 7 Day | -11.1% | -2.7% | -3.2% |
| 30 Day | -12.5% | -0.5% | -0.8% |
| 90 Day | 27.5% | 7.3% | 3.1% |
| 1 Year | -22.7%-22.7% | 32.9%31.8% | 42.0%38.9% |
| 3 Year | -89.6%-89.6% | 76.8%72.3% | 60.6%50.3% |
| 5 Year | -97.2%-97.2% | 151.1%132.6% | 128.0%102.5% |
Long-Term Price Volatility Vs. Market
How volatile is Aethlon Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall St
We're Hopeful That Aethlon Medical (NASDAQ:AEMD) Will Use Its Cash Wisely4 months ago | Simply Wall St
Aethlon Medical (NASDAQ:AEMD) Is In A Good Position To Deliver On Growth Plans8 months ago | Simply Wall St
Could The Aethlon Medical, Inc. (NASDAQ:AEMD) Ownership Structure Tell Us Something Useful?Valuation
Is Aethlon Medical undervalued compared to its fair value and its price relative to the market?
2.43x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AEMD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AEMD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AEMD is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: AEMD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AEMD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AEMD is good value based on its PB Ratio (2.4x) compared to the US Medical Equipment industry average (5.3x).
Next Steps
Future Growth
How is Aethlon Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-47.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AEMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AEMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AEMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AEMD's revenue is expected to decline over the next 3 years (-8.2% per year).
High Growth Revenue: AEMD's revenue is forecast to decline over the next 3 years (-8.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AEMD's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Aethlon Medical performed over the past 5 years?
-2.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AEMD is currently unprofitable.
Growing Profit Margin: AEMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AEMD is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare AEMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AEMD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.8%).
Return on Equity
High ROE: AEMD has a negative Return on Equity (-64.82%), as it is currently unprofitable.
Next Steps
Financial Health
How is Aethlon Medical's financial position?
Financial Position Analysis
Short Term Liabilities: AEMD's short term assets ($12.3M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: AEMD has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AEMD is debt free.
Reducing Debt: AEMD has no debt compared to 5 years ago when its debt to equity ratio was 16.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AEMD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AEMD has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 2.6% each year.
Next Steps
Dividend
What is Aethlon Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AEMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AEMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AEMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AEMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AEMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.3yrs
Average management tenure
CEO
Chuck Fisher (73 yo)
0.33
Tenure
US$159,000
Compensation
Dr. Charles J. Fisher, Jr., also known as Chuck, M.D. has been Chief Executive Officer of Aethlon Medical, Inc. since October 30, 2020. He founded and serves as the Chief Executive Officer of Margaux Biolo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Director & Member of Extracorporeal Therapy Advisory Board | 0.33yr | US$159.00k | 0.13% $ 36.4k | |
| CFO, Senior VP of Finance & Secretary | 10.42yrs | US$354.75k | 0.020% $ 5.5k | |
| Senior VP | 2.67yrs | US$69.00k | 0.12% $ 32.6k | |
| Head of Clinical Studies | 15.92yrs | no data | no data | |
| Chief Medical Officer | 0.083yr | no data | no data | |
| Consultant | no data | no data | no data |
0.3yrs
Average Tenure
68yo
Average Age
Experienced Management: AEMD's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Director & Member of Extracorporeal Therapy Advisory Board | 0.33yr | US$159.00k | 0.13% $ 36.4k | |
| Senior VP | 2.67yrs | US$69.00k | 0.12% $ 32.6k | |
| Chairman of the Board | 0.33yr | US$79.00k | 0.14% $ 39.3k | |
| Member of Extracorporeal Therapy Advisory Board | no data | no data | no data | |
| Member of Extracorporeal Therapy Advisory Board | no data | no data | no data | |
| Member of Extracorporeal Therapy Advisory Board | no data | no data | no data | |
| Member of Sepsis & Inflammation Advisory Board | no data | no data | no data | |
| Member of Extracorporeal Therapy Advisory Board | no data | no data | no data | |
| Independent Director | 7.67yrs | US$78.00k | 0.063% $ 17.7k | |
| Member of Extracorporeal Therapy Advisory Board | no data | no data | no data | |
| Member of Sepsis & Inflammation Advisory Board | no data | no data | no data | |
| Member of Sepsis & Inflammation Advisory Board | no data | no data | no data |
3.0yrs
Average Tenure
62yo
Average Age
Experienced Board: AEMD's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AEMD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31%.
Top Shareholders
Company Information
Aethlon Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aethlon Medical, Inc.
- Ticker: AEMD
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$28.127m
- Shares outstanding: 12.12m
- Website: https://www.aethlonmedical.com
Number of Employees
Location
- Aethlon Medical, Inc.
- 9635 Granite Ridge Drive
- Suite 100
- San Diego
- California
- 92123
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AEMD | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Mar 1999 |
| EJU | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Mar 1999 |
| EJU | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 1999 |
Biography
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopur...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/02/26 00:01 |
| End of Day Share Price | 2021/02/25 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.